



Provider Notification

Updates Regarding Additional Doses of the COVID-19 Vaccine

On Aug. 12, 2021, the Food and Drug Administration (FDA) amended the emergency use authorizations (EUAs) for both the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine. This amendment allows for the use of an additional dose following an initial two-dose primary series of mRNA COVID-19 vaccine in certain immunocompromised individuals, specifically:

- Solid organ transplant recipients
- Those diagnosed with conditions considered to have an equivalent level of immunocompromise

The FDA's amendment **does not** apply to people who are not immunocompromised. For more information, please see the [full article](#).

Additionally, on Aug. 13, 2021, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) unanimously recommended a third dose of mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna) after an initial two-dose primary series for immunocompromised individuals. See the [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#) for more information.

For vaccine claims and encounters, states should ensure their Medicaid and Children's Health Insurance Program (CHIP) providers use Current Procedural Terminology (CPT) code 003A for Pfizer vaccine and 0013A for the Moderna vaccine. Find more information on [COVID-19 vaccines and coding](#). State Medicaid and CHIP agencies also must cover COVID-19 vaccine administration with no cost sharing for nearly all enrollees during the COVID-19 public health emergency (PHE) and generally for over a year after it ends. This coverage also should include the administration of an additional vaccine dose for those who are immunocompromised. In addition, the American Rescue Plan Act of 2021 (ARP) provides a temporary 100% federal medical assistance percentage (FMAP) and CHIP-enhanced FMAP for amounts expended by a state for medical assistance for COVID-19 vaccines and their administration. Please refer to the Coverage and Reimbursement of COVID-19 Vaccines, Vaccine Administration, and Cost Sharing under Medicaid, the Children's Health Insurance Program and Basic Health Program toolkit for more information:

<https://www.medicaid.gov/state-resource-center/downloads/covid-19-vaccine-toolkit.pdf>

The Center for Medicaid & CHIP Services (CMCS) is available to provide technical assistance to states and is ready to review and process all state plan amendments needed to implement payment policies for a third dose of a COVID-19 vaccine. Humana will also continue to monitor COVID-19 vaccination recommendations and provide further updates as they are available.